Rydapt®

Active substance

Midostaurin (PKC412)

Holder

Novartis Pharma

Status

Closed

Indication

Newly diagnosed FLT3 mutated acute myeloid leukemia patients eligible for standard induction and consolidation chemotherapy.

Public documents

Approbation

Information for the patient

Informed consent

Last update

09/10/2018
Last updated on 13/02/2024